HIV, viral hepatitis and STI epidemics, particularly among people who inject drugs and other key populations, continue to be fuelled by laws and policies criminalizing sex work; drug use or possession; diverse forms of gender expression and sexuality; stigma and discrimination; gender discrimination...; violence; lack of community empowerment and other violations of human rights. These sociostructural factors limit access to health services, constrain how these services are
delivered and diminish their effectiveness.
more
Towards ending tuberculosis and multidrug-resistant tuberculosis.
DHS Working Papers No. 103
Guidance statement
Recommendations on contraceptive methods used by
women at high risk of HIV
Die Filme wurden produziert mit dem Ziel, Informationen über mögliche Folgen von traumatischen Ereignissen und entsprechende Behandlungsmöglichkeiten zu verbreiten.
Die Filme können kostenlos auf der Stiftungswebsite heruntergeladen werden.
Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries (LMIC). The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in LMIC. Barriers at the... patient, health-care provider, and health system level prevent the implementation of optimal primary and secondary prevention. Identification of the particular barriers that exist in resource-constrained settings is necessary to inform effective strategies to reduce the identified evidence-practice gaps. Furthermore, targeting modifiable factors that contribute most significantly to the global burden of CVD, including tobacco use, hypertension, and secondary prevention for CVD will lead to the biggest gains in mortality reduction. We review a select number of novel, resource-efficient strategies to reduce premature mortality from CVD, including: (1) effective measures for tobacco control; (2) implementation of simplified screening and management algorithms for those with or at risk of CVD, (3) increasing the availability and affordability of simplified and cost-effective treatment regimens including combination CVD preventive drug therapy, and (4) simplified delivery of health care through task-sharing (non-physician health workers) and optimizing self-management (treatment supporters). Developing and deploying systems of care that address barriers related to the above, will lead to substantial reductions in CVD and related mortality.
more
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
The guidelines are primarily intended for health-care professionals working in first- or second-level health-care facilities, including emergency, inpatient and outpatient services. They are also directed at policy-makers, health-care planners and programme managers, academic institutions, non-gover...nmental and civil society organizations to inform capacity-building, teaching and research agendas.
Web annex A provides the quantitative evidence reports, Web annex B summarizes the qualitative and economic evidence and Web annex C presents the Evidence-to-Decision frameworks.
more
This handbook is designed to provide essential information as well as quick tips to improve foot care for people with dark skin tone living with diabetes.
Building on the WHO guidelines for disclosure to children up to age 12 in 2011, this implementation guidance provides evidence on existing interventions that support children and adolescents living with HIV in the process of disclosure. It includes interventions that focuses on safe disclosure, as w...ell as supporting children and adolescents with onwards disclosure. Specifically, this brief collates existing interventions via a scoping review; assesses key interventions through a realist evaluation lens, identifying what works, for whom, and in what contexts; and highlights emerging considerations, key gaps, and key actions.
more
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment.